CN1742741A - Medicinal composition containing amino glucose and calcium agent and vitamin D and use thereof - Google Patents
Medicinal composition containing amino glucose and calcium agent and vitamin D and use thereof Download PDFInfo
- Publication number
- CN1742741A CN1742741A CN 200510041469 CN200510041469A CN1742741A CN 1742741 A CN1742741 A CN 1742741A CN 200510041469 CN200510041469 CN 200510041469 CN 200510041469 A CN200510041469 A CN 200510041469A CN 1742741 A CN1742741 A CN 1742741A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- calcium
- glucosamine
- preparation
- calcium preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention discloses a medicine composite containing aminoglucose, calcium agent and vitamin D as effective active components and different auxiliary materials, said medicine composite can be used for preventing and curing osteoporosis and osteoarthropathy, and can be made into various do sage forms of tablet, capsule, soft capsule and microcapsule, etc.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, specifically is that a kind of to contain with glucosamine and calcium preparation and vitamin D be the drug combination preparation of effective active composition, and the application of this pharmaceutical composition in treatment and prevention of osteoporosis disease and osteoarthritis.
Background technology
(osteoarthritis OA) is common a kind of chronic arthritis to osteoarthritis, and people are always at the medicine of seeking and explore control osteoarthritis PD for many years.Germany in 1969 is clinical verification glucosamine sulfate (glucosaminesulfate first; GS) treatment osteoarthritis; observe the result that glucosamine sulfate is treated knee osteoarthritis through several short distance and long-range randomized, double-blind; show that this product can anti-inflammatory analgesic; the effect that delays the knee osteoarthritis development is arranged again; experiment in vitro confirms that again it has good effect to cartilage metabolism, so glucosamine sulfate is considered to first medicine that changes the osteoarthritis state of an illness (being Chondroprotective agents again).
Glucosamine (Glucosamine) is present state internal therapy and prevention osteoarthritis medicine, it is the Main Ingredients and Appearance that constitutes chondrocyte, optionally act on osteoarthritis, have treatment and the effect of repairing connective tissue, anti-inflammatory analgetic, its anti-inflammatory analgetic effect is similar to nonsteroidal anti inflammatory medicine (as ibuprofen), but do not have the latter's untoward reaction such as gastrorrhagia, and toleration is good.Because of it can reduce symptoms such as osteoarthritis swelling that gout etc. causes, pain, ankylosis, significantly improve patient's quality of life and receive an acclaim.
Osteoporosis is one of common disease, causes serious harm for patient and society.Calcium deficiency is the major reason that causes osteoporosis, and therefore, calcium preparation share separately or with other drug and can treat and prevention of osteoporosis, and vitamin D has the normal calcification that promotes calcium absorption and utilization and bone.
Along with the development of China's aged tendency of population process, old medication has become the emphasis of the world of medicine's research.Osteoarthritis and osteoporosis are as global commonly encountered diseases and frequently-occurring disease, bring great misery to the patient, cause very big pressure to society, very high in China's osteoarthritis and osteoporosis sickness rate, account in the population of population more than 10%, 50 years old sickness rate especially up to 60%～70%.In view of osteoarthritis and osteoporosis are frequently-occurring diseases common among the crowd at advanced age, both morbidities have influence mutually, imagination is prepared into compound preparation with glucosamine and calcium preparation and vitamin D, both improved curative effect, reduced medicining times again, be convenient to patient, reduced drug cost, had important clinical treatment meaning and social benefit for the orthopaedics common frdquently encountered disease for the treatment of based on osteoarthritis and osteoporosis.
Summary of the invention
Technical problem to be solved by this invention is the deficiency at the compound preparation that does not still have at present treatment and prevention of osteoporosis disease and osteoarthritis clinically, proposed glucosamine and calcium preparation and vitamin D are combined into compound preparation and various drug combination preparation method thereof, such pharmaceutical preparation can be used for treatment and prevention of osteoporosis disease and osteoarthritis, both improved curative effect, and reduced medicining times again, be convenient to patient, reduced drug cost.
A kind of pharmaceutical composition and formulation preparation method thereof that contains glucosamine and calcium preparation and vitamin D is to adopt following scheme to realize:
The pharmaceutical composition that contains glucosamine and calcium preparation and vitamin D is characterized in that with glucosamine and calcium preparation and vitamin D be the effective active composition, its raw material weight mixing ratio scope:
Glucosamine 1-100 part
Calcium preparation 1-100 part
Vitamin D 0.01-100 part
Calcium preparation is one or more in the following calcium containing compound: calcium citrate, calcium carbonate, calcium chloride, calcium gluconate, calcium lactate, dalcium biphosphate, calcium levulinate etc.; Glucosamine can adopt glucosamine sulphate or hydrochlorate, phosphate or its mixture replacing; Vitamin D is selected from vitamin D1, D2, D3 or its mixture.
The described pharmaceutical composition that contains glucosamine and calcium preparation and vitamin D is characterized in that its raw material preferred weight ratio range:
Glucosamine 10-100 part
Calcium preparation 10-100 part
Vitamin D 0.01-50 part.
The described pharmaceutical composition that contains glucosamine and calcium preparation and vitamin D is characterized in that its raw material preferred weight ratio range:
Glucosamine 50-100 part
Calcium preparation 50-100 part
Vitamin D 0.01-20 part.
Described pharmaceutical composition, it is characterized in that, its dosage form is the multiple dosage form that can realize on the pharmaceutics, comprises tablet, capsule, soft capsule, microcapsule, dispersible tablet, gel, gel inhalant, oral liquid, suspensoid, middle agent, patch, ointment, pill, powder, cataplasma, injection, infusion solution, freeze dried injection, lipidosome injection, target administration injection, suppository, slow/controlled release preparation.
Described pharmaceutical composition is characterized in that described dosage form is tablet, capsule, its raw material weight mixing ratio scope:
Glucosamine 1-100 part
Calcium preparation 1-100 part
Vitamin D 0.01-100 part
Excipient 1-50 part
Disintegrating agent 1-50 part
Binding agent 1-50 part
Described excipient is a kind of in sucrose, lactose, microcrystalline Cellulose, dextrin, mannitol, starch or the calcium phosphate or two kinds; Described disintegrating agent is a kind of in hyprolose, carboxymethyl starch sodium, polyvinylpolypyrrolidone or the cross-linking sodium carboxymethyl cellulose or two kinds; Described binding agent is a polyvinylpyrrolidone, sodium carboxymethyl cellulose, a kind of in the starch or two kinds.
Above-mentioned dosage form is tablet, capsule, its raw material preferred weight ratio range:
Glucosamine 10-100 part
Calcium preparation 10-100 part
Vitamin D 0.01-50 part
Excipient 1-40 part
Disintegrating agent 1-40 part
Binding agent 1-40 part.
Above-mentioned dosage form is tablet, capsule, its raw material preferred weight ratio range:
Glucosamine 50-100 part
Calcium preparation 50-100 part
Vitamin D 0.01-20 part
Excipient 1-20 part
Disintegrating agent 1-20 part
Binding agent 1-20 part.
The above pharmaceutical composition can be used for treating and prevention of osteoporosis disease and osteoarthritis.
The present invention can improve its curative effect by glucosamine and calcium preparation and vitamin D are prepared into compound preparation, reduces medicining times, is convenient to patient, reduces drug cost.
The specific embodiment
The following examples can make those skilled in the art more fully understand the present invention, but do not limit the present invention in any way.
The preparation of embodiment 1 glucosamine calcium citrate dispersible tablet
Glucosamine 40 grams
Calcium citrate 40 ± 5 grams
Vitamin D3 1000U
Carboxymethyl starch sodium: microcrystalline Cellulose (1: 2) 15 ± 3 grams
Polyvinylpyrrolidone 1 ± 0.5 gram
Mannitol 4 ± 1 grams
Get above-mentioned supplementary material wet granulation and cross 20 mesh sieves, 20 mesh sieves are crossed in oven dry, add the micropowder silica gel mix homogeneously, tabletting.
The capsular preparation of embodiment 2 glucosamine calcium citrates
Glucosamine 40 grams
Calcium citrate 40 ± 5 grams
Vitamin D3 1000U
Microcrystalline Cellulose 10 ± 3 grams
Lactose 10 ± 3 grams
Carboxymethyl starch sodium 6 ± 2 grams
10% starch slurry is an amount of
Magnesium stearate 1 ± 0.5 gram
Micropowder silica gel 1 ± 0.5 gram
Get glucosamine and calcium citrate and cross the 80-120 mesh sieve, microcrystalline Cellulose, lactose, carboxymethyl starch sodium is crossed 100 mesh sieves respectively, with glucosamine and calcium citrate, vitamin D and above-mentioned adjuvant mix homogeneously, with 10% starch slurry is binding agent system soft material, cross 20 sieve series granules, but wet granular is in 50 ℃ of baking oven forced air dryings; Dried granule is crossed 20 mesh sieve granulate, and with magnesium stearate and micropowder silica gel mixing, fill is in capsule.
Claims (8)
1, the pharmaceutical composition that contains glucosamine and calcium preparation and vitamin D is characterized in that with glucosamine and calcium preparation and vitamin D be the effective active composition, its raw material weight mixing ratio scope:
Glucosamine 1-100 part
Calcium preparation 1-100 part
Vitamin D 0.01-100 part
Calcium preparation is one or more in the following calcium containing compound: calcium citrate, calcium carbonate, calcium chloride, calcium gluconate, calcium lactate, dalcium biphosphate, calcium levulinate etc.; Glucosamine can adopt glucosamine sulphate or hydrochlorate, phosphate or its mixture replacing; Vitamin D is selected from vitamin D1, D2, D3 or its mixture.
2, the pharmaceutical composition that contains glucosamine and calcium preparation and vitamin D according to claim 1 is characterized in that its raw material preferred weight ratio range:
Glucosamine 10-100 part
Calcium preparation 10-100 part
Vitamin D 0.01-50 part.
3, the pharmaceutical composition that contains glucosamine and calcium preparation and vitamin D according to claim 1 is characterized in that its raw material preferred weight ratio range:
Glucosamine 50-100 part
Calcium preparation 50-100 part
Vitamin D 0.01-20 part.
4, according to claim 1,2 or 3 described pharmaceutical compositions, it is characterized in that, its dosage form is the multiple dosage form that can realize on the pharmaceutics, comprises tablet, capsule, soft capsule, microcapsule, dispersible tablet, gel, gel inhalant, oral liquid, suspensoid, electuary, patch, ointment, pill, powder, cataplasma, injection, infusion solution, freeze dried injection, lipidosome injection, target administration injection, suppository, slow/controlled release preparation.
5, pharmaceutical composition according to claim 4 is characterized in that described dosage form is tablet, capsule, its raw material weight mixing ratio scope:
Glucosamine 1-100 part
Calcium preparation 1-100 part
Vitamin D 0.01-100 part
Excipient 1-50 part
Disintegrating agent 1-50 part
Binding agent 1-50 part
Described excipient is one or more in sucrose, lactose, microcrystalline Cellulose, dextrin, mannitol, starch or the calcium phosphate; Described disintegrating agent is one or more in hyprolose, carboxymethyl starch sodium, polyvinylpolypyrrolidone or the cross-linking sodium carboxymethyl cellulose; Described binding agent is a polyvinylpyrrolidone, sodium carboxymethyl cellulose, one or more in the starch.
6, the pharmaceutical composition that contains glucosamine and calcium preparation and vitamin D according to claim 5 is characterized in that its raw material preferred weight ratio range:
Glucosamine 10-100 part
Calcium preparation 10-100 part
Vitamin D 0.01-50 part
Excipient 1-40 part
Disintegrating agent 1-40 part
Binding agent 1-40 part.
7, the pharmaceutical composition that contains glucosamine and calcium preparation and vitamin D according to claim 5 is characterized in that its raw material preferred weight ratio range:
Glucosamine 50-100 part
Calcium preparation 50-100 part
Vitamin D 0.01-20 part
Excipient 1-20 part
Disintegrating agent 1-20 part
Binding agent 1-20 part.
8, the described pharmaceutical composition that contains glucosamine and calcium preparation and vitamin D of one of claim 1～7, the application in treatment and prevention of osteoporosis disease and osteoarthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510041469 CN1742741A (en) | 2005-08-09 | 2005-08-09 | Medicinal composition containing amino glucose and calcium agent and vitamin D and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510041469 CN1742741A (en) | 2005-08-09 | 2005-08-09 | Medicinal composition containing amino glucose and calcium agent and vitamin D and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1742741A true CN1742741A (en) | 2006-03-08 |
Family
ID=36138366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510041469 Pending CN1742741A (en) | 2005-08-09 | 2005-08-09 | Medicinal composition containing amino glucose and calcium agent and vitamin D and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1742741A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101904866A (en) * | 2010-09-07 | 2010-12-08 | 许阳 | Medicinal composition for treating osteoporosis and preparation method thereof |
| CN101606922B (en) * | 2009-07-06 | 2011-01-05 | 山西康宝生物制品股份有限公司 | Glucosamine potassium sulfate microcapsule and preparation method and application thereof |
| CN105535944A (en) * | 2015-12-29 | 2016-05-04 | 徐州市铜山区生命科学研究院 | Medical and edible composite health medicine for preventing and controlling osteoporosis and articular degeneration and preparation method of medical and edible composite health medicine |
| CN106109490A (en) * | 2016-08-02 | 2016-11-16 | 辽宁康辰药业有限公司 | One increases bone density, prevents and treats osteoporotic tablet and preparation method thereof |
| CN110448538A (en) * | 2019-09-09 | 2019-11-15 | 山东润德生物科技有限公司 | N-acetylglucosamine capsule preparations and preparation method thereof |
| CN110973639A (en) * | 2019-12-25 | 2020-04-10 | 中国农业科学院特产研究所 | Deer bone collagen antioxidant peptide chelated calcium tablet and preparation method thereof |
-
2005
- 2005-08-09 CN CN 200510041469 patent/CN1742741A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101606922B (en) * | 2009-07-06 | 2011-01-05 | 山西康宝生物制品股份有限公司 | Glucosamine potassium sulfate microcapsule and preparation method and application thereof |
| CN101904866A (en) * | 2010-09-07 | 2010-12-08 | 许阳 | Medicinal composition for treating osteoporosis and preparation method thereof |
| CN105535944A (en) * | 2015-12-29 | 2016-05-04 | 徐州市铜山区生命科学研究院 | Medical and edible composite health medicine for preventing and controlling osteoporosis and articular degeneration and preparation method of medical and edible composite health medicine |
| CN106109490A (en) * | 2016-08-02 | 2016-11-16 | 辽宁康辰药业有限公司 | One increases bone density, prevents and treats osteoporotic tablet and preparation method thereof |
| CN110448538A (en) * | 2019-09-09 | 2019-11-15 | 山东润德生物科技有限公司 | N-acetylglucosamine capsule preparations and preparation method thereof |
| CN110448538B (en) * | 2019-09-09 | 2021-03-02 | 山东润德生物科技有限公司 | N-acetylglucosamine capsule preparation and preparation method thereof |
| CN110973639A (en) * | 2019-12-25 | 2020-04-10 | 中国农业科学院特产研究所 | Deer bone collagen antioxidant peptide chelated calcium tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1805738A (en) | Extended-release tablets of metformin | |
| CN1742741A (en) | Medicinal composition containing amino glucose and calcium agent and vitamin D and use thereof | |
| CN1092986C (en) | CoA oral preparation for reducing blood fat and its preparation method | |
| CN1297304C (en) | Aquilarid distillate suspensoid agent and its preparation method | |
| CN1833652A (en) | Sustained release composns preparation of Fudosteine and clarithromycin | |
| CN101125147B (en) | Glucosamine calcium medicine preparation, preparation method and application thereof | |
| CN1840010A (en) | Minipill for treating gastric disease and preparation method thereof | |
| CN1817346A (en) | Benzoyl metronidazole dispersion tablets and preparation thereof | |
| CN100342860C (en) | Actacid composition | |
| CN1188126C (en) | Preparation of composite motidine dispersant pills | |
| CN1068519C (en) | Medicinal composition for curing ulcer of upper digestive tract and effectively inhibiting recurrance thereof | |
| CN1742726A (en) | Piperazine ferulate oral cavity disintegrating tablet and preparing method | |
| CN1078468C (en) | Health-care products composition | |
| CN1245163C (en) | Puerarin dispersing tablet composition and its preparation method | |
| CN1704062A (en) | Sustained release tablet of oleanolic acid and its preparation method | |
| CN1857289A (en) | Dispersed compound tablet of glycyrrhizic acid and glycyrrhizinate and its preparing process | |
| CN1259904C (en) | Medicinal composition with sodium houttuy fonate and ambroxol hydrochloride | |
| CN1872160A (en) | Sloly released tablet of red sage root, and preparation method | |
| CN1679616A (en) | Compound tablet for treating gastritis and preparation thereof | |
| CN1742719A (en) | Bilobanoate oral-cavity disintegrating tablet and preparation method | |
| CN1526384A (en) | Quickly disintegrated fenofibrate oral prepn | |
| CN1732910A (en) | Chewing tablet of tramado hydrochloride and its preparation method | |
| CN1593398A (en) | Daidzein dispersible tablet composition and its preparation process | |
| CN101073572A (en) | Medicinal composition for treating cold wet numbness and its production | |
| CN1626089A (en) | Valaciclovir oral desintegration tablet and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |